86170-47-0

Upstream product

• 100-39-0 benzyl bromide 
• 2283-08-1 2-hydroxy-1-naphthalenecarboxylic acid 

Downstream Products

• 279245-95-3 2-[2-(4'-chlorobiphenyl-4-ylsulfanyl)ethoxy]naphthalene-1-carboxylic acid benzyl ester 
• 485799-93-7 2-[2-(3'-cyanomethyl-biphenyl-4-ylsulfanyl)-ethoxy]-naphthalene-1-carboxylic acid benzyl ester 
• 279245-96-4 2-[2-(4'-chlorobiphenyl-4-sulfonyl)ethoxy]naphthalene-1-carboxylic acid benzyl ester 
• 485799-94-8 2-[2-(4'-methoxy-biphenyl-4-sulfonyl)-ethoxy]-naphthalene-1-carboxylic acid benzyl ester 
• 279246-23-0 2-[2-(4-(4-methoxyphenyl)phenylsulfanyl)ethoxy]naphthalene-1-carboxylic acid benzyl ester 
• 485799-97-1 2-[2-(3'-cyanomethyl-biphenyl-4-sulfonyl)-ethoxy]-naphthalene-1-carboxylic acid 
• 485799-91-5 2-[2-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]propyloxy]-N-hydroxy-1-naphthalenecarboxylic acid 

Relevant academic research and scientific papers

A simple and effective method for chemoselective esterification of phenolic acids

A new method for efficient and chemoselective esterification of phenolic acids in KHCO3/alkyl halide/DMF reaction system is described, by which a series of phenoic acid esters were obtained in excellent yields.

NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability

The NMR-based discovery of biaryl hydroxamate inhibitors of the matrix metalloproteinase stromelysin (MMP-3) has been previously described (Hajduk et al. J. Am. Chem. Soc. 1997, 119, 5818-5827). While potent in vitro, these inhibitors exhibited no in vivo activity due, at least in part, to the poor pharmacokinetic properties of the alkylhydroxamate moiety. To circumvent this liability, NMR-based screening was implemented to identify alternative zinc-chelating groups. Using this technique, 1-naphthyl hydroxamate was found to bind tightly to the protein (KD = 50 μM) and was identified as a candidate for incorporation into the lead series. On the basis of NMR-derived structural information, the naphthyl hydroxamate and biaryl fragments were linked together to yield inhibitors of this enzyme that exhibited improved bioavailability. These studies demonstrate that the NMR-based screening of fragments can be effectively applied to improve the physicochemical or pharmacokinetic profile of lead compounds.

Inhibitors of matrix metalloproteinases

Compounds having the formula and pharmaceutically acceptable salts and prodrugs thereof are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a ma